FDA international travel policy
International travel for FDA employees should be restricted to "essential" meetings in these non-"routine" times, Commissioner McClellan clarifies in March 24 memo. "Examples of 'essential' would include meetings where significant regulatory policy decisions will be made that will impact the Agency directly and where the policy decision would be expected to be different were FDA personnel not there to represent the Agency's position. 'Essential' does not include routine attendance at a conference, routine speeches, outreach, training, routine meetings of working groups, etc.," the memo says...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”